dermatomyositis

dermatomyositis
Name	Dermatomyositis
Field	Dermatology; Rheumatology
Symptoms	Heliotrope rash; Gottron papules; proximal muscle weakness
Complications	Interstitial lung disease; malignancy
Onset	Any age; bimodal peaks in childhood and middle adulthood
Causes	Autoimmune; paraneoplastic associations
Prognosis	Variable; depends on malignancy and ILD

dermatomyositis Dermatomyositis is an inflammatory myopathy characterized by distinctive cutaneous findings and symmetric proximal muscle weakness. It occurs across age groups with pediatric and adult forms, often involving systemic features and associations with internal malignancy and interstitial lung disease. Management integrates immunosuppression, dermatologic care, and oncologic screening, with outcomes influenced by comorbid conditions.

Signs and symptoms

Patients commonly present with a violaceous heliotrope eruption of the eyelids and erythematous Gottron papules over extensor surfaces, accompanied by symmetric proximal limb weakness affecting activities such as rising from a chair or climbing stairs. Cutaneous manifestations may include shawl sign or V-sign photosensitivity and poikiloderma, while systemic features such as dysphagia, arthralgia, and constitutional fatigue reflect involvement beyond skin and muscle. Extra-muscular complications often manifest as interstitial lung disease with cough and dyspnea or paraneoplastic syndromes detected during evaluation for occult neoplasm.

Causes and pathophysiology

Dermatomyositis is considered an autoimmune microangiopathy with complement-mediated damage to capillaries and perimysial inflammation leading to muscle fiber ischemia and perifascicular atrophy. Triggering factors include viral infections, environmental exposures, and associations with malignancies such as ovarian, lung, colorectal, and breast cancer, implicating paraneoplastic mechanisms. Genetic predisposition interacts with humoral and cellular immunity, with myositis-specific autoantibodies (including anti-Mi-2, anti-MDA5, anti-TIF1-γ, and anti-NXP2) correlating with distinct clinical phenotypes and complications such as rapidly progressive interstitial lung disease or cancer-associated myositis.

Diagnosis

Diagnosis combines clinical assessment, serologic testing, electromyography, imaging, and tissue biopsy. Laboratory evaluation includes measurement of serum muscle enzymes such as creatine kinase and aldolase and testing for myositis-specific autoantibodies that guide prognosis and malignancy screening. Electromyography and MRI of affected muscles identify inflammatory changes, while skin or muscle biopsy demonstrates interface dermatitis, capillary dropout, and perifascicular atrophy characteristic of the condition. Given the recognized association with occult neoplasia, age-appropriate cancer screening is integral to initial and ongoing evaluation.

Treatment

First-line therapy typically involves high-dose corticosteroids to control muscle inflammation, often combined early with steroid-sparing agents such as methotrexate or azathioprine to reduce cumulative glucocorticoid exposure. Refractory or severe cases, including those with rapidly progressive interstitial lung disease or severe cutaneous disease, may require intravenous immunoglobulin, rituximab, mycophenolate mofetil, or cyclophosphamide, coordinated with pulmonary and oncologic management when indicated. Adjunctive measures include physical therapy, sun protection for photosensitive eruptions, topical corticosteroids or calcineurin inhibitors for cutaneous disease, and vaccination and infection prophylaxis in the setting of immunosuppression.

Prognosis and complications

Prognosis varies from chronic relapsing disease with functional impairment to recovery with treatment; factors predicting poorer outcomes include older age at onset, delay in treatment, extensive interstitial lung disease, and paraneoplastic association. Major complications include progressive interstitial lung disease leading to respiratory failure, treatment-related infections, calcinosis (especially in juvenile cases), dysphagia with aspiration risk, and malignancy-related morbidity and mortality. Long-term multidisciplinary follow-up addresses rehabilitation, surveillance for cancer recurrence, and management of chronic immunosuppression side effects.

Epidemiology

Dermatomyositis shows a bimodal age distribution with peaks in childhood and middle adulthood and a female predominance. Incidence estimates vary globally but generally fall within a rare-disease range, with geographic and ethnic variation reported in cohort studies and population registries. Associations with specific cancers and differing prevalence of autoantibody subsets contribute to heterogeneity in clinical cohorts across regions and referral centers.

Category:Autoimmune diseasesCategory:Muscle disordersCategory:Skin conditions